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Abstract 
Background: Tobacco smoking is a major cause of morbidity and mortality among people living with 
HIV (PLHIV). Due to the limited success of standard abstinence-focused smoking cessation strategies 
in this population, there is growing interest in tobacco harm reduction (THR) approaches as an 
additional strategy to address these high smoking rates. This study explored the attitudes of health 
practitioners who provide healthcare to PLHIV towards THR.  
Methods: 179 Australian health practitioners who provide healthcare to PLHIV completed an online 
survey that measured their attitudes towards THR approaches, including switching from cigarettes to 
e-cigarettes or vaporised nicotine products (VNPs). 
Results: Respondents supported the concept of THR but were undecided on the role of VNPs. 
Respondents most commonly reported ‘don’t know’ or ‘undecided’ responses to statements regarding 
VNPs. More respondents, however, agreed than disagreed that switching from smoking to long-term 
vaping could reduce risk (36% and 22% respectively) and be an effective strategy to help PLHIV to 
quit smoking (37% agree and 17% disagree). Only a minority of respondents (20%) agreed that VNPs 
are too harmful to recommend to patients, however around half (53%) were undecided. 
Conclusions: Despite supporting the principle of THR, health practitioners may require more 
evidence and knowledge about VNPs before being willing to consider them as a suitable intervention 
strategy.   
 
  
  
1. INTRODUCTION 
1.1. HIV and smoking  
Early detection and access to antiretroviral therapy has greatly increased life expectancies for people 
living with HIV (PLHIV) (Nakagawa et al., 2013). However, the reduction in HIV-related mortality 
has been accompanied by an increase in mortality in this population from non-HIV causes, such as 
tobacco-related disease (Helleberg et al., 2013). PLHIV are 2-3 times more likely to smoke (Fuster et 
al., 2009; Mdodo et al., 2015; Shirley et al., 2013), experience greater nicotine dependency (Lifson 
and Lando, 2012) and are less likely to quit (Mdodo et al., 2015) than the general population. Despite 
this, many PLHIV want to quit smoking (Humfleet et al., 2009) and identifying effective intervention 
strategies is critical to realising the optimum health outcomes that are possible for PLHIV on 
antiretroviral therapy (Helleberg et al., 2015). The limited effectiveness of existing smoking cessation 
strategies among PLHIV (Pool et al., 2016) suggests a need to investigate new approaches, such as 
tobacco harm reduction (THR).  
 
1.2. Tobacco harm reduction and vaporised nicotine products  
A THR approach aims to reduce tobacco-related morbidity and mortality without requiring complete 
abstinence (Eversman, 2015; McNeill and Munafo, 2013; National Institute for Health and Care 
Excellence (NICE), 2013; Tobacco Advisory Group of the Royal College of Physicians, 2007). 
Potential THR strategies include smoking reduction or switching from smoking cigarettes to long-
term use of lower risk nicotine products, such as nicotine replacement therapy (NRT) (Eversman, 
2015; National Institute for Health and Care Excellence (NICE), 2013) or vaporised nicotine products 
(VNPs), also known as e-cigarettes. 
 
Use of VNPs as cessation aids or long-term cigarette substitutes, has increased in recent years 
although they are not currently approved or marketed as medicines. Between 48% (Kandra et al., 
2014) and 65% (Steinberg et al., 2015) of US physicians report being asked by patients about e-
cigarettes and such evidence has resulted in guidelines for practitioners responding to such requests 
(Mendelsohn and Gartner, 2015). Nonetheless, VNPs remain contentious (McNeill, 2016; Meernik 
and Goldstein, 2016) with opponents highlighting uncertainty around long-term safety, and expressing 
fear they will renormalise smoking, thus potentially encouraging uptake among young people 
(Morphett et al., 2016; van der Eijk, 2016).  
 
Despite an emerging body of research on practitioner views of VNPs, (Brown-Johnson et al., 2016; 
Cummins et al., 2016; El-Shahawy et al., 2016; Pepper et al., 2014; Sherratt et al., 2016; Van Gucht 
and Baeyens, 2016) studies have not examined such views in the context of the PLHIV care 
providers. Furthermore, despite there being a number of THR options, research of practitioner 
  
attitudes has predominately focused on VNPs. We assessed attitudes of Australian health practitioners 
who provide healthcare to PLHIV towards THR in general and a range of specific THR options for 
addressing smoking among their patients living with HIV.  
 
2. METHODS 
2.1. Participants 
Any health practitioner providing healthcare to PLHIV in Australia at the time of completing the 
survey was eligible to participate. Email invitations and newsletter advertisements were distributed 
nationally through HIV-related clinical networks and professional organisations. A brief description 
of the study was distributed with a hyperlink to the online participant information and following 
consent, the survey.   
 
2.2. Survey 
The 10-15 minute survey was based on previous studies with health practitioner groups (Ford et al., 
2015) and input from a PLHIV advocacy organization, the NSW Ministry of Health Tobacco Control 
Section, and tobacco control and HIV researchers and clinicians. Survey data was collected in 
Research Electronic Data Capture (REDCap) and measured: 
1. Respondent characteristics.   
2. Frequency of performing 5A framework activities for smoking cessation (Ask, Assess, 
Advise, Assist and Arrange) (The Royal Australian College of General Practitioners, 2011) 
with patients living with HIV. 
3. How smoking status is recorded and used. 
4. Attitudes toward addressing smoking cessation with their patients living with HIV and THR 
approaches. 
5. Knowledge and use of smoking cessation services provided by state-based, community 
PLHIV organisations.  
After completing the survey, participants were redirected to a separate page (to maintain anonymity of 
survey responses) to enter an optional prize draw and to indicate whether they would like a summary 
of the study’s results. 
 
2.3. Ethical considerations 
All respondents were required to acknowledge having read the study information and confirm consent 
prior to accessing the survey. Respondents were not required to provide identifying information to 
participate. The study was approved by The University of Queensland's, School of Public Health 
Research Ethics Committee (Approval Number: SB06112015).  
 
2.4. Analysis 
  
Data was analysed in SPSS (IBM Corp., Released 2015). Incomplete (N=40) and ineligible (no 
current clinical caseload of PLHIV) (N=6) surveys were removed. Attitude statements were collected 
on a 6 point likert scale (strongly agree, somewhat agree, neither agree nor disagree, somewhat 
disagree, strongly disagree, don’t know). For simplification, responses were grouped into 3 
categories: agree, disagree and neutral (‘neither agree nor disagree’ and ‘don’t know’). This 
manuscript reports the findings concerning THR approaches.  
 
3. RESULTS 
3.1. Participant characteristics 
Respondents included 179 people, of which 62.5% were medical practitioners, 28.5% registered 
nurses and 10.1% other practitioners (i.e. psychologists, dentists). Approximately 84% of the medical 
practitioners were antiretroviral therapy prescribers. Most respondents’ (96.1%) were non-smokers 
and primarily practiced in metropolitan regions (64.8%). Approximately half had received brief 
intervention smoking cessation training (47.5%) and 58.1% worked solely in the public sector. 
 
3.2. Practitioner attitudes  
Most respondents agreed that harm reduction (non-abstinence) strategies for cigarette smoking could 
benefit PLHIV who are unable or unwilling to quit smoking (87%) and most disagreed that abstinence 
should be the only goal discussed (71%), see Figure 1. Cutting down the number of cigarettes smoked 
per day was endorsed by a majority of respondents (72%) as an effective strategy to substantially 
reduce the risk of smoking-related diseases, as was switching from smoking cigarettes to using NRT 
as a long-term substitute (79%). 
 
Figure 1. Practitioner attitudes to tobacco harm reduction 
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More respondents provided a neutral response than agreed or disagreed to statements on VNPs, 
however, indicating substantial uncertainty about these products. Only 36% agreed that switching to 
VNPs could reduce health risk, while 43% provided a neutral response. More respondents also 
provided a neutral response to whether VNPs were effective (46%) at helping people to quit compared 
to agreed (37%) or disagreed (17%). Similarly, most respondents were neutral as to whether VNPs 
were too harmful to recommend (53%), while 27% disagreed and 20% agreed.  
 
4. DISCUSSION 
4.1. Support for THR  
The present study found large in principle support for incorporating THR approaches into clinical 
practice when addressing smoking among PLHIV. The level of support is in stark contrast to other 
studies, for example, a US survey of primary care physicians and specialists (oncologists, 
cardiologists and pulmonologists) revealed that only 36% supported the concept of THR (Steinberg et 
al., 2015). The long history of harm reduction approaches in the field of HIV prevention (Ball, 2007; 
Wodak and McLeod, 2008; World Health Organization (WHO), 2011) could explain this difference.  
 
4.2 Uncertainty for VNP as THR  
Despite in principle support for THR, most respondents in the current study expressed uncertainty 
towards VNPs, a finding supported elsewhere. In a qualitative research study of those with interest 
and expertise in smoking and THR (for example scientists, politicians and tobacco control advocates) 
there was consensus on the features of ‘good’ harm reduction products, but division as to whether 
such a product exists (Martin et al., 2004). The study also found medicinal products, such as NRT 
were agreed to be the safest current product for THR (Martin et al., 2004). Our study also indicated 
greater support for long-term substitution with NRT compared with other harm reduction strategies, 
an approach supported by the UK's National Institute for Health and Care Excellence (National 
Institute for Health and Care Excellence (NICE), 2013).  
 
A greater proportion of respondents supported VNPs as a quit aid (37%) than did not. This is 
consistent with levels of support reported in international samples of other health practitioner groups, 
such as quitline counsellors (32%) (Cummins et al., 2016) and tobacco counsellor and general 
practitioner samples (38%) (Van Gucht and Baeyens, 2016).  
 
Similarly, more respondents in the current study agreed than disagreed that switching to VNPs could 
reduce risk for smokers. Although 36% agreed that switching from smoking to long-term VNP use 
can reduce the risk of smoking-related disease and 37% agreed that VNPs may be an effective 
strategy to help people to quit smoking, only 27% disagreed that these products were too harmful to 
recommend to smokers, while around half provided a neutral response (53%). Other studies have also 
  
reported mixed, but generally negative views about the safety of switching from smoking to vaping 
among health practitioners. A qualitative analysis of online patient-provider communications about e-
cigarettes reported that overall, 47% of provider statements of e-cigarettes were negative, and 20% 
were positive (Brown-Johnson et al., 2016). Most of the online patient queries related to safety and 
side effects and the majority of responses to these queries were negative. However, the majority of 
responses in that study were positive when discussing e-cigarettes as a harm reduction or smoking 
cessation aid. While surveyed GPs and tobacco counsellors in the US believed that e-cigarettes are 
less harmful than tobacco cigarettes, they still thought that they were associated with harm (Van 
Gucht and Baeyens, 2016). For example, 87% agreed that the risk of cancer is lower for vaping than 
for smoking but 46% still agreed e-cigarettes were carcinogenic (Van Gucht and Baeyens, 2016).  
 
Most smokers in a recent survey reported that doctors are the most trustworthy source for e-cigarette 
safety information (Wackowski et al., 2015) and doctors regularly respond to patient queries, yet 
many do not feel confident in doing so (Sherratt et al., 2016) in part due to a lack of knowledge (El-
Shahawy et al., 2016). Health practitioners may also believe either that sufficient evidence is not 
available or they are not familiar with the emerging evidence on the safety and efficacy of VNPs as a 
quit aid or harm reduction tool. Training and education about these products may be needed to enable 
health practitioners to respond to patient queries about them (Bascombe et al., 2016). More research 
evidence on the relative health impacts of switching from smoking to vaping compared to continuing 
to smoke and stopping smoking by other means would also help clarify the risks and benefits for 
smokers considering this strategy. 
 
Attitudes and advice to patients about VNPs have previously been shown to vary by country 
(Cummins et al., 2016) and may reflect prevailing attitudes toward THR in various countries. The low 
level of support for recommending VNPs as a THR strategy in our study may also reflect the 
Australian policy context, where no VNPs have been approved as therapeutic goods (Douglas et al., 
2015; National Health and Medical Research Council (NHMRC), 2015). 
 
4.3. Strengths and limitations   
Due to the use of a convenience sample, the results of this study may not be representative of the 
broader population of health practitioners who provide healthcare to PLHIV and respondents may 
over-represent those with an interest in smoking cessation. A response rate cannot be calculated 
because it is unknown how many health practitioners viewed the invitation to participate due to the 
use of advertisements and snowballing methods. However, our sample size was comparable to other 
cross-sectional studies of health practitioners in HIV research in Australia (Mao et al., 2013). This 
study provides important data on the emerging topic of THR advice for smokers in clinical 
interactions. It also allowed examination of health practitioner views toward different THR 
  
approaches separately (cutting down, long-term substitution with NRT and VNPs) and therefore 
provides a more nuanced understanding that is lacking from previous studies.  
 
4.4. Conclusions and future research  
This study provides insight into health practitioner’s views on THR and novel approaches to reducing 
smoking-related harms among PLHIV, a high priority population group whose medical care is 
shifting towards the ongoing management of their health condition as a chronic illness. Respondents 
were supportive of THR but uncertain of switching to VNPs as a THR approach, possibly due to 
concerns regarding safety. Greater support was expressed for long-term NRT use, possibly due to 
existing knowledge that NRT is safe and effective for smoking cessation. Health practitioners may 
require more evidence and knowledge about VNPs before forming a firm opinion (either for or 
against) on their use for THR.  
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